DocGo (DCGO) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
14 May, 2026Strategic positioning and business model
Delivers technology-enabled mobile healthcare and medical transportation at scale, serving patients at home, office, or community settings across 31 states and the UK.
Proprietary technology backbone integrates with leading EHRs, supports dynamic fleet management, and offers patient-facing mobile apps.
Vertical integration includes clinical practice, laboratory licensure, and efficient billing with Medicare, Medicaid, and commercial payers.
Unique value proposition for healthcare systems, payers, and providers, focusing on care gap closure, transitions of care, and remote patient monitoring.
Financial performance and growth
Annual revenues have shown strong growth from 2021 to 2025, with 2026 guidance indicating continued expansion.
Q4 2025 revenue reached $74.9M, with a 32.5% adjusted gross margin and $11.3M adjusted EBITDA loss.
Mobile health segment revenue was $24.8M with a 31.8% adjusted gross margin; medical transportation segment revenue was $50.2M with a 32.8% margin.
Record volumes achieved in all major business lines, including significant increases in healthcare in the home and virtual care services.
Market opportunity and demand drivers
Chronic disease management is a major U.S. healthcare challenge, driving demand for mobile and remote care solutions.
Total addressable market for at-home care estimated at $250B, with 30% of PCP market expected to shift to nontraditional providers.
Medical transportation market estimated at $7–$13B in the U.S.
Growth strategy leverages long-term customer relationships, payer programs, virtual care, and disciplined M&A.
Latest events from DocGo
- Tech-driven healthcare platform posts strong growth, raises guidance, and targets profitability.DCGO
21st Annual Needham Technology, Media, & Consumer Conference14 May 2026 - Q1 revenue was $75.6M, net loss widened, but 2026 guidance was raised on strong core growth.DCGO
Q1 202611 May 2026 - Key votes include director elections, reverse stock split, and auditor ratification for 2026.DCGO
Proxy filing23 Apr 2026 - Proxy seeks approval for director elections, reverse stock split, and key governance amendments.DCGO
Proxy filing22 Apr 2026 - Key proposals include director elections, a reverse stock split, and governance amendments.DCGO
Proxy filing10 Apr 2026 - 2026 guidance raised on core growth and SteadyMD gains, with H2 profitability targeted.DCGO
Q4 202516 Mar 2026 - Scaling tech-enabled mobile healthcare with record volumes and strong growth outlook.DCGO
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - All proposals passed, with strong financials and strategic growth initiatives outlined.DCGO
AGM 20243 Feb 2026 - Q2 revenue up 31% to $164.9M, net income and margins rose, and cash flow guidance increased.DCGO
Q2 20242 Feb 2026